The purpose of this study is to evaluate the metabolism, the routes and extent of elimination, and drug levels of \[14C\]Navlimetostat (BMS-986504) in healthy female participants
Participants must have a body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive.
Participants must have a recent history (ie, last month) of a minimum of 1 bowel movement per 2 days.
Participants must be female (as assigned at birth) who is an individual not of childbearing potential (INOCBP), defined as one of the following:.
Participants must not have any significant acute or chronic medical illness.
Participants must not have current or recent gastrointestinal disease.
Participants must not have a history of prolonged bleeding or excessive bruising.
Other protocol-defined Inclusion/Exclusion criteria apply.